Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;67(11):e296-e297.
doi: 10.46747/cfp.6711e296.

Le sémaglutide pour la perte pondérale

[Article in French]
Mo Ojeniran  1 , Betty Dube  1 , Allison Paige  2 , Joey Ton  3 , Adrienne J Lindblad  4
Affiliations

Le sémaglutide pour la perte pondérale

[Article in French]
Mo Ojeniran et al. Can Fam Physician. 2021 Nov.
No abstract available

PubMed Disclaimer

References

    1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay Iet al. . Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989. - PubMed
    1. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva Aet al. . Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325(14):1403-13. - PMC - PubMed
    1. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault Let al. . Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971-84. - PubMed
    1. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen Cet al. . Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325(14):1414-25. - PMC - PubMed
    1. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DRet al. . Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381(9):841-51. - PubMed

LinkOut - more resources